2 active not recruiting, 2 withdrawn, 1 completed, 1 recruiting. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 2, Withdrawn 2, Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Withdrawn 2, Active not recruiting 1 |
Follow Progressive Disease: new trials by email Literature Review of Progressive Disease trials Research Report on Progressive Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology - Astrocytoma, Glioblastoma | Phase 1 | Recruiting | Masonic Cancer Center, University of Minnesota | 9 | 2026-04-23 | 2026-05-01 |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer Binimetinib, Brigatinib - ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma | Phase 1 | Terminated | University of California, San Francisco | 3 | 2020-02-25 | 2022-10-17 |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies Pembrolizumab, Autologous dendritic cells, Interleukin-2 - Mesothelioma, Malignant, PD-L1 Negative | Phase 1 | Active not recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 18 | 2019-12-12 | 2024-10-01 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Cetuximab, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2019-06-14 | 2026-06-11 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Copanlisib, Niraparib - Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 31 | 2019-04-29 | 2026-07-23 |
Disease Progression (7) · Astrocytoma (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Mesothelioma, Malignant (1) · Myelodysplastic Syndromes (1) · Neoplasm, Residual (1)
Disease Attributes (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Neoplasms (6) · Neoplasms by Site (4) · Neoplasms by Histologic Type (3) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Lung Diseases (2) · Neoplasms, Glandular and Epithelial (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Adenoma (1) · Adnexal Diseases (1)
Biopsy (1) · Blood Specimen Collection (1) · Cetuximab (1) · Cyclophosphamide (1) · Hydroxychloroquine (1) · Interleukin-2 (1) · Nivolumab (1) · binimetinib (1) · brigatinib (1) · copanlisib (1) · devimistat (1) · encorafenib (1) · fludarabine (1) · niraparib (1) · pembrolizumab (1)
M.D. Anderson Cancer Center (3) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Masonic Cancer Center, University of Minnesota (1) · University of California, San Francisco (1) · Wake Forest University Health Sciences (1)
United States (6) · Italy (1)
Bayard Powell, MD (1) · Collin Blakely, MD, PhD (1) · Jin S Im (1) · Massimo Guidoboni, MD (1) · Shannon N Westin (1) · Van K Morris (1)
P30CA012197 (1), P30CA016672 (1)